Objectives: The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC) will take part in the clinical trial IMMOMEC. To the scientific part, MCMCC will cooperate in comprehensive research on biomarkers for clinical and immunological treatment responses.
Expertise relevant to the proposed work: Expertise relevant to the proposed work: MCMCC is the leading Polish comprehensive cancer center, as well as the primary government research institution devoted solely to oncology. Founded in 1932 by Maria Sklodowska-Curie, and currently it is divided into 9 specialized clinical departments responsible for the diagnostics and therapy of different tumor types. The research departments are devoted to experimental therapies, epidemiology and prevention, pathology, imaging and basic research in the cancer biology. In 2011, in MCMCC, 28000 patients were treated the inpatient clinics; another 26000 patients – in the One Day Chemotherapy Section, and as more than 340 000 outpatient visits were recorded.
The Department of Soft Tissue/Bone Sarcoma and Melanoma, MCMCC is the major Polish comprehensive center in the field of the treatment and research in sarcoma and melanoma. In MCMCC approximately 300 new cases of melanoma and more than 10 patients with Merkel Cell Carcinoma are treated in combined modalities every year. MCMCC has participated in numerous clinical trials (phase II and III) and translational research in close cooperation with international research groups, e.g.: EORTC Soft Tissue and Bone Sarcoma Group (e.g. EORTC 62027, 62024) and EORTC Melanoma Group (e.g. EORTC 18952, 18961, 18032), or pharmaceutical-company sponsored (as CAMN107G2201, DERMA). In 1995, MCMCC was the first center in Poland to introduce sentinel lymph node biopsy in the clinical management of cutaneous melanoma into everyday practice. MCMCC also participates in preparing both Polish and international recommendations for sarcoma and melanoma patients.
Specific role in the project: MCMCC will actively contribute patients with Merkel cell carcinoma to the clinical trial as well as dissemination of the final results of our projects; thus MCMCC is involved in WP1 and WP2.